Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxytocin intranasal - OT4B

Next Previous
Drug Profile

Oxytocin intranasal - OT4B

Latest Information Update: 30 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aix-Marseille University; CRMR PRADORT; Inserm Transfert
  • Developer CRMR PRADORT
  • Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prader-Willi syndrome

Most Recent Events

  • 30 Mar 2026 OT4B plans for possible drug registration for Prader Willi syndrome in Europe and the rest of the world (OT4B pipeline, March 2026)
  • 01 Mar 2025 Efficacy, adverse events and pharmacodynamics data from a clinical OT2SUITE follow-up trial in Prader Willi syndrome released by CRMR PRADORT
  • 31 Dec 2018 CRMR PRADORT completes a clinical OT2SUITE follow-up trial in Prader Willi syndrome (In children) in France (Intranasal) (NCT03081832)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top